Eli Lilly to Invest Over $1 Billion in India to Expand Global Manufacturing Capacity

US pharmaceutical giant Eli Lilly and Company has announced a major investment of more than $1 billion in India over the next several years to significantly expand its manufacturing and supply chain capabilities. This strategic move aims to leverage India’s skilled pharmaceutical workforce and network of contract manufacturers to bolster Lilly’s global production of essential medicines, including treatments for diabetes, obesity, Alzheimer’s disease, cancer, and autoimmune disorders.

Investment Details and Strategic Goals

The company plans to collaborate with multiple local Indian drugmakers specializing in complex pharmaceutical manufacturing, such as injectables and vials, under contract. As part of this initiative, Eli Lilly will establish a new manufacturing and quality control hub in Hyderabad. This facility will oversee contract manufacturing operations across India and provide advanced technical capabilities.

Patrik Jonsson, Executive Vice President and President of Lilly International, emphasized the significance of India in Lilly’s global manufacturing strategy: “We are making significant investments to increase manufacturing and medicine supply capacity around the world. India will play a critical role in supporting our evolving portfolio and capability building within our global network.” Hiring for the Hyderabad center is slated to begin immediately, with job roles including engineers, chemists, analytical scientists, quality control specialists, and managerial positions.

Context and Background

Although Eli Lilly launched its blockbuster weight-loss drug Mounjaro in India earlier in 2025, it currently does not operate its own manufacturing facilities in the country. Instead, India’s vibrant pharmaceutical industry—which ranks as the world’s third largest—is home to many contract manufacturers capable of producing complex medications at scale.

The investment in India aligns with a broader global expansion program by Lilly. Since 2020, the firm has committed more than $55 billion worldwide to build and expand production capacity, including a $5 billion facility investment in Virginia and plans for four new manufacturing plants across the US by 2030. This expansion is partially motivated by recent US government measures imposing a 100% tariff on imported branded drugs, encouraging domestic manufacturing growth.

Implications for Public Health

Eli Lilly’s manufacturing expansion in India aims to increase global access to important medications, particularly for chronic conditions such as diabetes and obesity, which are growing health concerns both in India and worldwide. India is expected to have the world’s second-largest population of obese individuals by 2050, driving demand for treatments like Mounjaro and potentially its upcoming oral weight-loss drug candidate, orforglipron.

By securing manufacturing and supply chain partnerships locally, Lilly hopes to ensure a steady and scalable supply of medicines globally, helping address public health challenges associated with non-communicable diseases. This increased production capacity may also reduce risks of supply chain disruptions and support more affordable access to innovative therapies.

Potential Challenges and Balanced Perspective

While the investment underscores confidence in India’s pharmaceutical ecosystem, it also positions Eli Lilly against a competitive landscape. Indian generic drug companies are gearing up to produce lower-cost alternatives to branded drugs like Wegovy once their patents expire, which may affect market dynamics for Lilly’s obesity and diabetes portfolio.

Moreover, the company has not disclosed specific details on the local manufacturing agreements or which drugs might be produced domestically. Regulatory approvals for new oral obesity treatments are anticipated from late 2025 onwards, with global launches potentially in 2026, introducing some uncertainty about exact product timelines and market reception.Expert Commentary

“Expanding manufacturing capacity in India is a smart strategy considering the country’s vast talent pool and existing pharmaceutical infrastructure. This could enhance global medicine availability and affordability if aligned with sustainable pricing models. However, vigilance is needed to balance innovation with access, especially where generic competition is strong.”

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References:

1. Reuters, “Eli Lilly to invest over $1 billion in India to expand manufacturing capacity,” October 6, 2025.